Observational studyScientific reports2022
Lipidic profiles of patients starting peritoneal dialysis suggest an increased cardiovascular risk beyond classical dyslipidemia biomarkers.
Observational study in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Sex-Specific Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Lipoprotein Combine Index Is Associated with Multi-Compartment Oxidative Stress in Clinically Stable Peritoneal Dialysis Patients: A Cross-Sectional Study.Biomedicines · 2026Article
- Clinical rationale behind glucose-sparing strategies in peritoneal dialysis: a narrative review.BMC nephrology · 2026Review
- Association between lipoprotein combine index and all-cause and cardiovascular mortality in patients undergoing peritoneal dialysis: a multicenter retrospective cohort study.Frontiers in nutrition · 2026Article
- A Prospective Study of Lipid Profile in Incident Patients on Peritoneal Dialysis.Arquivos brasileiros de cardiologia · 2026Article
- Hypertension is associated with an increased risk of peritoneal dialysis-associated peritonitis: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- The relationship between serum lipid levels and diabetic nephropathy in patients with primary diabetes.BMC nephrology · 2025Article
- A lipid atlas of the human kidney.Science advances · 2025Article
- Causal role of the plasma lipidome in the occurrence and progression of chronic kidney disease: a two-sample Mendelian randomization study.Diabetology & metabolic syndrome · 2025Article
- Risk prediction of cardiovascular events in peritoneal dialysis patients.BMC nephrology · 2025Article
- Faecal lipid profile as a new marker of fat maldigestion, malabsorption and microbiota.Pediatric research · 2024Observational
- Serum Malondialdehyde-Modified Low-Density Lipoprotein Level May Be a Biomarker Associated with Aortic Stiffness Among Patients Undergoing Peritoneal Dialysis.Life (Basel, Switzerland) · 2024Article
- Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes.Biomedicines · 2024Review
- Characteristics, Physiopathology and Management of Dyslipidemias in Pregnancy: A Narrative Review.Nutrients · 2024Review
- Peritoneal Dialysis Aggravates and Accelerates Atherosclerosis in UremicJournal of the American Heart Association · 2024Article
- Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.Redox biology · 2023Article
- Metformin Monotherapy Alters the Human Plasma Lipidome Independent of Clinical Markers of Glycemic Control and Cardiovascular Disease Risk in a Type 2 Diabetes Clinical Cohort.The Journal of pharmacology and experimental therapeutics · 2023Observational
- Methods on LDL particle isolation, characterization, and component fractionation for the development of novel specific oxidized LDL status markers for atherosclerotic disease risk assessment.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients on peritoneal dialysis (PD) have an increased risk of cardiovascular disease (CVD) and an atherogenic lipid profile generated by exposure to high glucose dialysis solutions. In the general population, the reduction of classic lipids biomarkers is associated with improved clinical outcomes; however, the same results have not been seen in PD population, a lack of data this study aims to fulfill. Single-center prospective observational study of a cohort of CKD patients who started renal replacement therapy with continuous ambulatory peritoneal dialysis. The differences in the lipid profile and analytical variables before and 6 months after the start of peritoneal dialysis were analyzed. Samples were analyzed on an Ultra-Performance Liquid Chromatography system. Thirty-nine patients were enrolled in this study. Their mean age was 57.9 ± 16.3 years. A total of 157 endogenous lipid species of 11 lipid subclasses were identified. There were significant increases in total free fatty acids (p < 0.05), diacylglycerides (p < 0.01), triacylglycerides, (p < 0.01), phosphatidylcholines (p < 0.01), phosphatidylethanolamines (p < 0.01), ceramides (p < 0.01), sphingomyelins (p < 0.01), and cholesterol esters (p < 0.01) from baseline to 6 months. However, there were no differences in the classical lipid markers, neither lysophosphatidylcholines, monoacylglycerides, and sphingosine levels. 6 months after the start of the technique, PD patients present changes in the lipidomic profile beyond the classic markers of dyslipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.